ProQR Therapeutics NV【PRQR】株式ニュース

PRQR is an Eli Lilly oligonucleotide RNA Editing Platform 17.1% ownership New Next generation Platform with huge indications like obesity and cardiovascular diseases Lily will be able to manufacture these drugs for them. Never Seen Lily own so much of a small cap company and make milestone payments on them so soon. These Milestones so far will reach close to 4 Billion dollars and payments have commenced.

Eli Lilly made a 25M Royalty payment in 2024 vs. $3.9B in potential milestone payments so far 5 more indications lily totaling 15 indications and cash runway for over the next 2.5 years. “Lilly” has 95 appearances in their annual report.

PRQR has 2 founders plus chief CMO from Analyam the leader in RNAI 31 Billion company
1. Martin Maier, PhD

Martin Maier, PhD, joined our board in 2024. Dr. Maier currently serves as Senior Vice President, Oncology at Alnylam Pharmaceuticals. Dr. Maier joined Alnylam in 2006 and has contributed to the development of lipid nanoparticles and GalNAc conjugates, two clinically validated platforms for siRNA delivery, and the advancement of multiple therapeutic programs to development, which has resulted in the approval of five RNAi therapeutic to date.

2.Phillip D. Zamore, PhD

Phillip is a Howard Hughes Medical Institute Investigator, Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the RNA Therapeutics Institute at the University of Massachusetts Medical School. He is also a co-founder of Alnylam Pharmaceuticals

3.John Maraganore, PhD, joined as a strategic advisor to our Board in March 2022. He served as the founding Chief Executive Officer and a Director of Alnylam from 2002 to 2021, where he built the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO®, GIVLAARI®, OXLUMO®, and Leqvio®. At Alnylam, he also led the company’s value creation strategy, building $ 25.0 billion in market capitalization

No other company has all key executives of Alnylam connected to any team in Biotech.

lastly

A. Peter Beal, PhD

Peter was appointed as ProQR's Chief ADAR Scientist in December 2024. Peter is a Professor in the Department of Chemistry at the University of California at Davis and Director of the NIH-funded UC Davis Chemical Biology Graduate Program. For over 25 years, work in the Beal laboratory has advanced understanding of the structures and mechanism of action for the ADAR enzymes responsible for adenosine to inosine RNA editing in humans. In addition, his group has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for recruitment of RNA-binding proteins including ADARs. Beal teaches organic chemistry at the undergraduate level and several classes in nucleic acids chemistry and chemical biology at the graduate level. He has authored over 100 peer-reviewed publications in the field of RNA chemical biology and mentored over 50 Ph.D. and M.S. degree students.

I will be buying up shares up to $2.00 today.

My thoughts are hold for 2 years you have a high probability of success maximizing profits and a buyout from LILY or Alnylam Pharmaceuticals. for 1.5-2 Billion similar to Roche buying Poseida for a total of 1.5 Billion last year early stage gene editing company.

PRQR has close to 30 Indications in their pipeline 15 of them with ELI Lilly

$PRQR